Research

Energy balance

Tirzepatide achieved similar 12-month TBWL% as R-ESG (13.2% vs. 13.4%, p = .9) and significantly more than semaglutide (13.2% vs. 8.1%, p = .04).

Tirzepatide may be a viable alternative for weight loss in patients post-sleeve gastrectomy, potentially outperforming semaglutide.

StrongSupportsmedium confidence
On subgroup analysis, tirzepatide achieved similar 12-months TBWL% as R-ESG (13.2% vs. 13.4%, p = .9) and significantly more than semaglutide (13.2% vs. 8.1%, p = .04).
Firas Bahdi et al. · Clinical Obesity · 2025

Why this rating

The study is a retrospective analysis with a significant sample size.

Source

Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy

Firas Bahdi et al. · Clinical Obesity · 2025

DOI 10.1111/cob.70001

cohort · n=90Cited 9×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →